Source: Wall Street

According to some scientists who have studied the drug, the method used to kill novel coronavirus is potentially dangerous and may limit the effectiveness of the drug. If this happens in the cells of patients treated with Molnupiravir, it could theoretically lead to cancer or birth defects.

MerckWhile the good news from the oral administration of COVID-19 's "miraculous medicine" Molnupiravir Phase III clinical practice is still causing repercussions in the stock market, the news that the new Mosadong drug is priced at 40 times the cost was buzzed earlier this week. On Thursday, Barron Weekly Barron's reported that some scientists worried that the drug could cause cancer or birth defects-its method of suppressing the virus could be rampant in the body.

Previous articles have specifically analyzed its pharmacological and clinical problems. Molnupiravir works by integrating itself into the genetic material of the virus and then causing a large number of mutations as the virus replicates, effectively killing it. In some laboratory tests, the drug has also been shown to integrate into the genetic material of mammalian cells, causing mutations when these cells replicate.

According to some scientists who have studied the drug, the method used to kill novel coronavirus is potentially dangerous and may limit the effectiveness of the drug. If this happens in the cells of patients treated with Molnupiravir, it could theoretically lead to cancer or birth defects.

Raymond Sinazi (Raymond Schinazi), professor of pediatrics and director of biochemical pharmacology at Emory University's Emory University, studied the drug during its development and published several papers on NHC, including articles showing that the drug can produce this response, insisting that it should not be used in young people-especially pregnant women-without more data.

Merck & Co Inc responded that the drug caused mutations in animal cell cultures in laboratory tests: he had conducted "extensive tests" on animals and said this should not be a problem.

"all the data from these studies show that molnupiravir has no mutagenicity or genotoxicity in the mammalian system in vivo." Merck & Co Inc company spokesman said. But Merck & Co Inc has not released any data on his animal research, but scientists believe that long-term research is needed to prove that the drug is really completely safe.

Merck & Co Inc had previously chosen to play down the safety risks of the drug, which had "strong safety", as Dr. Scott Gottlieb said in an interview on the day Merck & Co Inc first announced the study.

ZeroHedge's evaluation of this is understandable! After all, assuming it is approved, the drug is widely expected to be one of the "most profitable drugs of all time"-which is one of the reasons why Merck's shares soared to double digits after listing.

SVB Leerink analysts warned that the questions about the drug's safety suggested that Merck & Co Inc's stock's reaction could be said to be "exaggerated" at the very least. Investors are clearly desperate for a new "magic medicine" (mRNA injections have proved to be far less effective than advertised) that they don't ask too many questions about safety, let alone question the data.